Call for Abstract
10th Annual Congress on Biomarkers, Clinical Research
& Therapeutics, will be organized around the theme “Latest advancements in the field of Biomarkers & Clinical Research”
Biomarkers 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers 2018
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Biomarkers are key molecular or cellular events which link a specific environmental exposure to a health outcome. Biomarkers play an important role in understanding the relationships between exposure to environmental chemicals, the development of chronic human diseases and the identification of sub-groups that are at increased risk of the particular disease. A biomarker is an appropriate tool which can be equitably measured and can act as an indicator for physiological as well as pathological progress or pharmacological response to any therapeutic intervention. Classical biomarkers detect quantitative alteration in blood pressure; blood lactate levels post exercises, and blood glucose in diabetes mellitus. A biomarker, or bio indicator, for the most part alludes to a quantifiable pointer of some organic state or condition. The term is additionally infrequently used to allude to a substance the nearness of which demonstrates the presence of a living being. Environmental Assessment also carried out in the natural or synthetic form as bio-monitoring. Encourage, life structures, life events for Interim analysis. Biomarkers are regularly measured and assessed to look at ordinary natural procedures, pathogenic procedures, or pharmacologic reactions to a restorative mediation.
Cancer biomarker alludes to a substance or process that is demonstrative of the potency of generation of tumor in the body. A biomarker might be a particle emitted by a tumor or a particular reaction of the body in the vicinity of disease. Hereditary, epigenetic, proteomic, glycomic and imaging biomarkers can be utilized for malignancy determination, anticipation and the study of disease transmission. In a perfect world, such biomarkers can be tested in non-obtrusively gathered bio-fluids like blood or serum.
Uses of Biomarkers in cancer medicine
§ Risk assessment
§ Prognosis and treatment predictions
§ Pharmacodynamics and pharmacokinetic
§ Monitoring treatment response
Uses of biomarkers in cancer research
§ Developing drug targets
§ Surrogate endpoints
A biomarker can be anything which can be precisely measured as a pointer of ordinary organic working, pathogenic ways or a medication reaction to a restorative medication intercession. Atomic biomarkers are the biomarkers for the most part in sub-atomic frame. Atomic biomarkers partake in different purposes, including illness analysis and visualization, forecast and computation of treatment reaction and wellbeing assessment. The atomic biomarkers are only being created and approved to be utilized as a part of medication improvement, and used to bolster endorsement of medication items.
Molecular Biomarkers Discovery: Biomarker disclosure requires exceedingly guaranteed distinguished proof of a biomarker particle with constant quantitative data to demonstrate which proteins are changing to a factually correlated degree in light of infection. The revelation of atomic biomarkers has grown new systems beginning from the underlying strides. In the main phase of biomarker disclosure procedures, examination relies on mass spectrometry systems to make unprejudiced, semi quantitative investigation of changes amongst solid and sick states. The slant of plausible sub-atomic biomarkers produced in the revelation stage is to be further substantiated because of the high false positive rate. It is done by supplemental more focused on and quantitative mass spectrometry procedures, for example, immuno fondness peptide enhancement.
§ New procedures for disclosure
§ Protein biomarker revelation
§ Clinical biomarker progresses
§ Biomarkers for pediatric maladies
§ Clinical examination of NGS tests
§ Mass spectrometry based biomarker revelation
- Track 3-1Molecular Biomarkers Discovery
Current genomics and biotechnology promise the development of biomarkers to a state to predict individual disease risk which enable early detection of disease and improve diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements which can be used to predict risk of diseases, to enable early detection of disease, to improve treatment selection and to monitor the outcome of therapeutic interventions. The major objective of the Human Genome Project was the identification and development of such biomarkers for ‘personalized, preventive and predictive medicine’.
The indicative process of the presence of cancer in the body is carried out by tools known as cancer biomarkers. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. There are different types of cancer where biomarkers have their application such as lung, melanoma, breast, colorectal, pancreas and many more. Biochemically, cancer biomarkers can be DNA (germline or somatic), RNA, proteins, peptides, hormones, metabolites and even biological processes such as apoptosis, angiogenesis or proliferation. There are three major types of cancer biomarkers based on their clinical use: prognostic, predictive, and pharmaco-dynamic markers.
A biomarker is a distinctive tool or agent which can be equitably measured as an indicator of commonly biological processes, pathogenic processes or a pharmacological response to a therapeutic intervention. Biomarkers can be used for many purposes including disease diagnosis and prognosis, prediction and assessment of treatment response. Also, Biomarkers are used as an indicator of a biological factor that represents either a sub-clinical manifestation, stage of the disorder, or a surrogate manifestation of the disease. The potential uses of this class of biomarkers include, firstly as identification of individuals destined to become affected or who are in the “pre-clinical” stages of the illness, secondly, reduction in disease heterogeneity in clinical trials or epidemiologic studies, third, reflection of the natural history of disease encompassing the phases of induction, latency and detection, and finally, target for a clinical trial.
Some diseases are:-
§ Autoimmune disease
§ Alzheimer's disease
§ Cardiovascular disease
§ Neurological disorder
§ Immunological disorder
The major uses of biomarkers in clinical investigation are in the form of clinical trials and monitoring. The entire spectrum of disease from the earliest indication to the terminal stages may be resonated through biomarkers. Field studies on biomarker are generally done on the environmental assessment based on aquatic contamination by seeing the aqua life or by understanding the normal habitat change of different organism. Biomarkers also show the best relationship between its response when compared to the health/ecological effect. It provides variety of human and animal materials principally through immuno-assays and quantitative PCR can be analytically determined at Biomarker Laboratory.
Growth research is fundamental research into tumor to recognize causes and create methodologies for aversion, analysis, treatment and cure. Growth investigations range from the study of disease transmission, sub-atomic bioscience to the execution of clinical trials to assess and think about utilizations of the different malignancy medicines. These applications incorporate surgery, radiation treatment, chemotherapy, hormone treatment, immunotherapy and consolidated treatment modalities, for example, chemo-radiotherapy. Beginning in the mid-1990s, the accentuation in clinical diseases explorations moved towards treatments derived from biotechnology research, for example, tumor immunotherapy and quality treatment.
The Biomarkers discover its important application in the field of clinical innovative work by contextual investigation and information administration as obvious through Biomarker meetings. The Bioethics and protected innovation right builds up the standards and standard of direct of theory concerning clinical approval of biomarkers. The fusion of biomarker in clinical trials for several health disorder conditions will advance a legitimate indicative and remedial approach using even the medicinal gadgets to recognize clinical biomarkers. Right now this is a blasting business. A large portion of the presumed associations like Pfizer, Parexel and Quintiles are into clinical innovative work. The organizations, doctor's facilities and clinical research associations are the problem areas for directing clinical research with its development rate expanding exponentially by an expected 75B$ by 2016.In clinical innovative work, clinical biomarkers are utilized as a part of contextual analysis and information administration, clinical trials and in therapeutic gadgets.
The part of Biomarkers in medication revelation and advancement is to comprehend the pathophysiology of ailment. Biomarkers can be a clinical instrument for medication disclosure and improvement by affirming the adequacy and security to the correct patient. Biomarkers can be utilized as a part of comprehension about the instrument of medication.
Biomarkers inquires about takes after a continuum that starts with disclosure and continues through approval to the possible execution of biomarkers in a clinical setting. Biomarker disclosure requires high certainty recognizable proof of biomarker applicants with concurrent quantitation data to demonstrate which proteins are changing to a factually significant degree in light of infection. Biomarker competitors distinguished in disclosure should be approved utilizing bigger example sets covering an expansive segment of patient companions. To maintain a strategic distance from a potential bottleneck connected with taking countless to approval, a confirmation step is utilized to screen potential biomarkers, to guarantee that lone and the most noteworthy quality leads from the disclosure stage are taken into the exorbitant approval arrange. The check arrangement requires a high throughput work process with at least specimen planning which gives both high specificity and affectability. Also, the confirmation stage can affirm that a specific philosophy is reasonable to be utilized as a part of the approval stage.
Clinical research is a branch of social insurance science which decides the well-being and adequacy (viability) of solutions, gadgets, analytic items and treatment regimens expected for human use. These might be utilized for counteractive action, treatment, findings or for calming side-effects of some sickness. Clinical research is unique in relation to clinical practice. In clinical practice built up medicines are utilized, while in clinical research confirmation is gathered to set up a treatment.
Clinical trials are tests done in clinical research. Such imminent biomedical or behavioral research thoughts in human members are intended to answer particular inquiries regarding biomedical or behavioral mediations, including new medications, (for example, novel antibodies, drugs, dietary decisions, dietary supplements and medicinal gadgets) and known intercessions which warrant additional studies and examinations. Clinical trials produce information on security and viability.
Biomarker testing is a group of tests which aims to look into the molecular signs of health so that doctors can plan the best care regimen. Biomarker testing can also be called as genetic testing or biomarkers testing. Biomarkers, a foundation of precision oncology, are very important in management of breast cancer, gastro-esophageal cancer and non-small cell lung cancer. Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients.
The advances in biomarker testing are mainly in the fields of genetic testing, cancers and other diseases in their diagnosis, treatment and imaging. In silico biomarkers, microRNA biomarkers and several other clinical biomarkers have evolved in the recent researches and have broadened the path for biomarker testing.
A medical device, which is often an in vitro device and which offers information required important for the safe and operative use of a respective drug administration or biological product is called a companion diagnostic. These devices help to determine whether a specific therapeutic product’s benefits to a patient will be of more importance that can overshadow any possible serious side effects or risks to treat a patient. These biomarkers congress invite the latest technologies and techniques to be brought into light. Partnership between cancer pharmaceutics and diagnostics is a sensitive relation as there are often miscommunications due to lack of knowledge on requirements and feasibilities. The strategies for Rx-Dx partnerships provide a good platform for sharing the knowledge. Development of in-vitro companion diagnostic devices and their commercialization is a rapidly budding area. These diagnostics are useful in the study of surgical oncology.
Translational prescription regularly alluded to as translational science, (of which it is a frame) is characterized by the European Society for Translational Medicine (EUSTM) as an interdisciplinary branch of the biomedical field bolstered by three primary columns: benchside, bedside and group. The objective of TM is to consolidate disciplines, assets, mastery and strategies inside these columns to advance upgrades in aversion, analysis and treatments. As needs be, TM is a very interdisciplinary field, the essential objective of which is to mix resources of different natures inside the individual columns keeping in mind that the end goal is to enhance the worldwide social insurance framework altogether.
One imperative part of Pathology in the assessment of bosom malignancy is biomarker testing, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).
Recently there has been an enhanced and advanced biomedical technology such as high-throughput molecular imaging and microarrays to monitor SNPs, gene and protein expressions, to provide exhaustive situations for individuals. The biological and medical status from such data sets, which are viewed as biomarkers in a wide sense to help in carrying out identification, association and prediction studies for phenotypes such as cancer subtypes, prognosis, treatment responsiveness and adverse reactions for personalized medicine.
A case report is an elaborate report of the symptoms, signs, disease diagnosis, treatment, and follow-up of an individual patient usually recorded in medical field. Case reports might comprehend a demographic profile of the patient, but typically mention any unusual or unique occurrences. In this conference case reports on biomarker diagnostics, drug discovery and imaging are discussed in detail with relevance to molecular and cancer biomarkers. Cancer biomarkers conferences are a big platform to study case reports of these in precision.
A key ingredient in successful entrepreneurship is self-knowledge. Biomarkers-2018 aims to bring together all existing and budding bio-entrepreneurs to share experiences and present new innovations and challenges within the cancer community. Each year, over a million companies operate in the world with about 5–10 of them being classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creations. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum which will bring experts in areas ranging from Biomarkers to signaling pathways to novel therapeutic approaches to the scientific hub.